Comparing Our DIO Model with a Lean Control.
Semaglutide and tirzepatide continue to drive progress in metabolic disease care, and there is a growing need to better define their biological effects and relevance in preclinical models.
In response, our Metabolism Disease Area Team further characterized our C57BL/6NHsd diet-induced obesity (DIO) model against our control.
Get the full details of our 4-week study of mice on incretin treatment, which covers:
- Body weight and body composition
- Glucose tolerance
- Key metabolic biomarkers
Complete the form to download your copy. You’ll learn how DIO mice and lean mice respond to semaglutide and tirzepatide against controls.
If you have any questions about the DIO model or our comprehensive range of support spanning contract breeding, preconditioning, biospecimen, or surgical services, or end-to-end disease pharmacology studies, please contact us for a free consultation.
